THERAVLINFO – Transpyrenean network of advanced therapies in non-Hodgkin lymphoma
THERAVLINFO is an advance in the biomedical translation of preclinical lymphoma knowledge and models generated in IMLINFO (EFA 281/16), in order to improve the survival and quality of life of patients with hematological cancer.
THERAVLINFO is a multidisciplinary network that seeks to strengthen the cooperation between 4 previous partners (2 hospitals and 2 research centers in Barcelona and Toulouse) and to foster new synergies with 1 research center in Navarra. It also collaborates with 2 biotechnology companies in the territory of POCTEFA.
A previous project called IMLINFO established a repository of samples from patients with non-Hodgkin’s lymphoma (NHL), developed a 3D culture platform that summarizes in vitro disease, and a workflow for antitumor drug screening. Targets involved in the evasion of anti-tumor immune response and immunosuppression have been identified.
- THERAVLINFO will improve 3D systems, develop drugs against these targets (antibodies, CAR-T cell therapy and nanocapsules) and validate their therapeutic potential in mouse models.
- THERAVLINFO involves the cooperation of experts in 3D multicellular cultures, animal models, multiparametric cytometry, confocal microscopy, omics technologies and computational analysis, and aims to promote the training of young researchers able to integrate and rotate between cross-border partners.
- THERAVLINFO develops cell therapies with the Hospital Clinic of Barcelona, and promotes collaborations with companies for the development of immunotherapies with antibodies (ONA Therapeutics) and new bioavailability and oral antibody delivery systems (NUCAPS).
In order to advance personalized medicine for patients with NHL who do not respond to standard treatment, have an early relapse or develop aggressive lymphoma, cross-border cooperation is essential to obtain materials from these patients in hospitals and develop new therapies.
Partners:
- Fundació de Recerca Clínic Barcelona-Institut d’Investigacions Biomèdiques August Pi i Sunyer, FRCB-IDIBAPS (Barcelone)
- Hospital Clínico de Barcelona, HCB (Barcelone)
- Université Toulouse III – Paul Sabatier UT3 (Haute Garonne)
- Centre Hospitalier Universitaire de Toulouse, CHUT (Haute Garonne)
- Universidad de Navarra, UNAV (Navarre)
Starting : 01 janvier 2024
dEnding : 31 décembre 2026
Coordinator : Institut de Recherches Biomédicales August (IDIBAPS), Barcelone-Espagne
UPS : partner, principal investigator : Christine Bezombes
CHU : partner, principal investigator : Pr Camille Laurent
This project is 65% co-financed by the European Regional Development Fund (ERDF) as part of the Interreg V-A Spain-France-Andorra POCTEFA 2021-2027 programme. The aim of the programme is to strengthen the economic and social integration of the Spain-France-Andorra border area. Its support focuses on the development of cross-border economic, social and environmental activities through joint strategies for sustainable territorial development.
